CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) (UNAUDITED) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 29, 2024	Oct. 01, 2023	Sep. 29, 2024	Oct. 01, 2023
Statement of Comprehensive Income [Abstract]
Net income/(loss) before allocation to noncontrolling interests		$ 4,473	$ (2,376)	$ 7,644	$ 5,518
Foreign currency translation adjustments, net		131	(109)	200	234
Unrealized holding gains/(losses) on derivative financial instruments, net		(303)	408	41	519
Reclassification adjustments for (gains)/losses included in net income/(loss)	[1]	(175)	(67)	(334)	73
Other comprehensive income, cash flow hedge, gain (loss), before tax, total		(477)	341	(293)	593
Unrealized holding gains/(losses) on available-for-sale securities, net		59	(83)	(17)	30
Reclassification adjustments for (gains)/losses included in net income/(loss)	[2]	(6)	51	80	(442)
Other comprehensive income (loss), available-for-sale securities, before tax, total		54	(32)	63	(411)
Reclassification adjustments related to amortization of prior service costs and other, net		(27)	(29)	(83)	(88)
Reclassification adjustments related to curtailments of prior service costs and other, net		(2)	(1)	(2)	(14)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax		(29)	(30)	(85)	(102)
Other comprehensive income/(loss), before tax		(322)	170	(115)	313
Tax provision/(benefit) on other comprehensive income/(loss)		(157)	36	(81)	(17)
Other comprehensive income/(loss) before allocation to noncontrolling interests		(166)	134	(35)	330
Comprehensive income/(loss) before allocation to noncontrolling interests		4,307	(2,242)	7,609	5,848
Less: Comprehensive income/(loss) attributable to noncontrolling interests		(3)	4	(2)	23
Comprehensive income/(loss) attributable to Pfizer Inc.		$ 4,310	$ (2,247)	$ 7,611	$ 5,826

[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.

[2] Reclassified into Other (income)/deductions—net.